StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
548 Study Matches

Biobehavioral Health Risk and Resilience in College Students (PSU THRIVE Study)

This protocol is designed to examine biobehavioral health risks, resilience, grit, forgiveness and well-being in college students.

No
 

Laura Klein
Laura Klein - at lcklein@psu.edu or 814-883-8624
Biobehavioral Health (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00006962
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Fulltime undergraduate student
18 to 24 years of age
English is a primary language

Exclusion Criteria:
Not enrolled as a full time undergraduate student
Under age of 18 years
Over age of 24 years
Not comfortable speaking English
Mental & Behavioral Health
I'm interested
Share via email

Developing a Recommendation System for Local Community Events

In this study, we investigate a recommender system for public, local events in Centre County, PA. Currently, there is no platform that aggregates all the events that take place in a community. The data is fragmented among many platforms and it can be difficult for people to find interesting things to do. Participants will interact with our software system and discuss their experiences through a survey and/or interview.

Yes
 

Tiffany Knearem
Tiffany Knearem - at tak54@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00014494
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 18 years or older
Must be a University Park student or local resident of Centre County

Exclusion Criteria:
Persons under 18 years of age
Persons who do not live in Centre County, PA
Education
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

PSCI 24-015 S2212 SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET), ARANDOMIZED PHASE III STUDY

To see if participants with early stage triple negative breast cancer randomized to receive anthracycline-free, taxane-platinum neoadjuvant chemotherapy with pembrolizumab have a better breast cancer event-free survival (BC-EFS)compared to participants randomized to taxane-platinum-anthracycline neoadjuvant chemotherapy with pembrolizumab.

keep all study appointmentsreport to your study team any side effects or any changes in medication

Yes
 

Cristina Truica
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05929768
STUDY00024644
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participants must have histologically confirmed ER-negative, PR-negative, and HER2-negative breast cancer
Participants must have breast and axillary imaging with mammogram and/or ultrasound and/or MRI within 49 days prior to randomization.
Participants must not have metastatic disease
Participants must not have received prior systemic therapy or radiation therapy
Participants must be ≥ 18 years old.

Exclusion Criteria:
Participants must not be pregnant or nursing.
Participants must not have a prior or concurrent malignancy
Participants must not have received a live vaccine within 30 days prior to randomization.
Participants must not have active autoimmune disease
Participants must not have severe or active infections
Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 2 locations

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,
Reading, PA ,

Behind virtual world building: Studying virtual reality environmental characteristics

This is a user study to investigate the environmental characteristics of virtual reality (VR). This study will provide empirical evidence of the essential characteristics based on users’ feedbacks. During your visit, you will receive a brief training about using a VR headset and navigating in the virtual environment. After the training, you will explore the virtual environment, complete tasks in VR, and answer questions regarding your feelings to our VR application.

Yes
 

Jiawei Huang
Jiawei Huang - at jzh87@psu.edu or 734-355-5327
Geography (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00011790
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
students at Penn State
healthy participants

Exclusion Criteria:
students that are cognitive impaired
students under 18
students with contagious disease
Education, Language & Linguistics
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Participants in this study will receive a drug called ribociclib with the endocrine therapy of your physician’s choice. Ribociclib is taken as a pill. Endocrine therapy is taken as a pill or given as a shot. You will have tests, exams and procedures that are part of your regular care and for study purposes. Also, as part of routine care, you will be checked every 4 to 12 weeks to make sure your cancer hasn’t come back. You will receive ribociclib combined with endocrine therapy for up to 3 years. After that you will continue endocrine therapy alone for another 2 years (5 years total) as part of your regular care.

Participants will be required to: - receive ribociclib along with standard endocrine therapy drugs - have blood drawn - imaging scans (CT, PET-CT, bone scans, mammograms, MRI) - keep a medication diary - optional biopsy - ECG-a test that looks at the way your heart beats - ECHO-a test that looks at the way your heart pumps

Yes
 

Monali Vasekar
PSCI-CTO at PSCI-CTO@pennstatehealth.psu.edu or 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05467891
STUDY00022070
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Written informed consent and HIPAA authorization for release of personal health information obtained prior to performing any study-specific screening procedures.
Male or female age ≥ 18 years at the time of consent.
ECOG Performance Status of 0-1 within 28 days prior to registration.
If patient is receiving tamoxifen or toremifene, a washout period of 28 days prior to registration is required.
Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer based on the most recently analyzed tissue sample and all tested by local laboratory.

Exclusion Criteria:
Patient with a known hypersensitivity to any of the excipients of ribociclib.
Patient who has received prior CDK4/6 inhibitor for recurrent disease. Patients who received a CDK4/6 inhibitor in the adjuvant setting may participate if they have been off therapy for at least 1 year prior to diagnosis of recurrent disease.
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.
Pregnant or breastfeeding or planning to become pregnant during the trial
Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety
Cancer
Experimental drug compared to an approved drug
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Phase Ib/11 Study of Propranolol with fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma

This research is being done to find out the safety of propranolol and, identify the maximum tolerated dose of propranolol that can be administered in combination with pembrolizumab in patients with unresectable stage III and stage IV melanoma. This study will evaluate this novel combination of pembrolizumab and propranolol to see what effect it may have on how your cancer responds to the treatment combination.

Phase II*propranolol twice a day.*pembrolizumab by an infusion every 3 weeks.*May receive treatment with pembrolizumab and propranolol for up to24 months from the time they began treatment with the combination.Procedures to be done:. A medical history  A physical exam ECOG Performance Status Perceived Stress Scale questionnaire An assessment of tumor by scan. Scans may include:o Computed tomography (CT), with or without contrast. o Magnetic resonance imaging (MRI) or head CT with IV contrast  Blood tests:o Approximately 2 tablespoons for routine testing, such as a complete blood count and acomprehensive metabolic panel Pregnancy test Urinalysis Electrocardiogram A sample of tumor from a previous biopsy or sample taken Phase 1 portion of the study, these evaluations/tests will also occur on Day 8 of Cycle 1 Review concomitant medications. Physical Exams ECOG Performance Status Perceived Stress Scale questionnaire Blood tests:o Every 3 weekso At 3 weeks and 6 months or discontinuation of treatment (whichever comes sooner) and atdisease progressiono Every 3 weeks: Approximately 1 tablespoon for tests that monitor your blood sugar levelsand thyroid functiono Every week for the first 6 weeks then every cycle for another 6 weeks Assessment of cancer by CT or MRI. These assessments will be performed every 12 weeks(± 14 days). The first assessment will be after completing Cycle 4. If their cancer is found to be improving,repeat the CT and MRI scans in about 12 weeks. EKG: Once treatment begins, this will be done every cycle prior to receiving pembrolizumab for the first 5 cycles. Adverse events Tumor Biopsy: A tumor biopsy (only in phase II) will be obtained at the 12 weeks after initiation oftreatment.Tumor biopsy will be optional for phase II patients..Safety Follow-Up:After all study treatment has stopped, end of treatmentvisit, which will be approximately 30 days after their last dose of study drug or before starting a newtreatment Medical History:  Concomitant medications complete physical examination ECOG Performance Status Perceived Stress Scale assessment Adverse events Survival status Blood tests:o Follow- Up Phase3 Month and 6 Month Follow- up After Treatment blood collected.The following assessments will be performed at 3 months and 6 months after the safety follow-up visit.Review concomitant medications Physical examination ECOG Performance Status Adverse events Survival Status Blood tests: CT of chest, abdomen and pelvis, or other areas as needed Long Term Survival Follow- Up:After your 3 month and 6 month follow up visits or if they progress, will be contacted every 6 months (±30 days)

Yes
 

Joseph Drabick
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03384836
STUDY00010009
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age >=18 years.
Participants must be newly diagnosed, treatment-naive with histologically confirmed stage IIIC unresectable melanoma or stage IV melanoma.
Have measurable disease per RECIST v1.1
Have an ECOG performance status 0-1

Exclusion Criteria:
Participants who have received previous immunotherapy for any cancer (excluding melanoma) including PD-1/PD-L1 inhibitors but not interferons and CTLA-4 inhibitors.
Participants with chronic autoimmune diseases
Other invasive cancers diagnosed < 3 years back that required systemic treatment. If diagnosed with other invasive cancer ≥ 3 years, should have complete recovery from all systemic toxicity except neuropathy and alopecia
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Advancing the use of immersive virtual environments to study the effects of racism on eating behavior in an Asian American population

During the COVID-19 pandemic, Asian Americans have faced a rise in overt racism, with thousands of hate incidents reported. This has had a bigger impact on young Asian American adults, leading to emotional distress and health problems. A theory by Harrell suggests that experiencing racial discrimination can harm mental and physical well-being due to stress. Past studies have shown a connection between racial discrimination stress and health issues like obesity and mental disorders. However, there's a need to understand the cultural and emotional factors involved. This research aims to explore how racial discrimination affects Asian Americans' food choices by looking at stress responses and cultural influences. Using surveys, experiments, psychophysiology, and virtual reality, the study will investigate how cultural identity affects stress reactions and subsequent food decisions after racial discrimination experiences.

Hello,We are recruiting Asian Americans with Japanese, Chinese, or Korean heritage for a paid research study.We want to understand how racism affects food choice in a virtual reality (VR) environment. To participate in this study, you will need to complete an informed consent form, and answer questions prior to your arrival at the lab. You will have to come to the lab to watch a video of anti-Asian racism incidents that happened during the COVID-19 pandemic, and answer questions before and after the video. Last, you will make food choices in the VR environment. Participation will require three hours or more of fasting before arrival at the lab.You will be paid $25 in a gift card for your participation. If you come to the lab but do not complete the study, you will still be paid.Please continue to the next page to read the informed consent if you are interested in participating. If you are not, please exit this page.https://redcap.link/lp1wq7uu

$25 Amazon gift card

Yes
 

Travis Masterson
Christina Blackmon - at cmb8633@psu.edu
Nutritional Sciences (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT00000000
STUDY00023365
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Self-identified as Asian American of Japanese, Chinese or Korean heritage
Aged between 18 and 21 at the start of the study
Born in the US or lived in the U.S. since your 10th birthday or earlier
Self-reported having fasted for at least 3 hours prior to the start of the study

Exclusion Criteria:
Not self-identified as Asian-American of Japan, China or Korea heritage
Not aged between 18 and 21 at the start of the study
Not born in the US or not having lived in the U.S. since your 10th birthday or earlier
Self-reported having fasted for less than 3 hours prior to the start of the study
Has epilepsy or a cognitive disability
Food & Nutrition, Mental & Behavioral Health
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Understanding the Media Literacy Competencies of Today’s College Students

This study will involve surveying college students regarding their media literacy competencies and experiences with media literacy education.

No
 

Hans Schmidt
Hans Schmidt - at hcs10@psu.edu or 610-892-1251
Academic Affairs (BRANDYWINE)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013446
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
College student
18 years of age or older

Exclusion Criteria:
Not 18 years of age or older
Education
I'm interested
Share via email

The perception and experiences of newly diagnosed type 2 diabetes patients (T2D) on the impact of patient-provider communication on subsequent decision to engage in diabetes self-management education (DSME).

This study seeks to explore the perception and experiences of newly diagnosed type 2 diabetes patients about how their interaction with their provider at diagnosis led to their uptake of diabetes education.

No
 

Michelle Boakye
Michelle Boakye - at mdb521@psu.edu or 814-699-1783
Nursing (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00014668
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18 or older
Any gender
Newly diagnosed type 2 diabetes patient within the past 12 months
Have attended at least one diabetes education after diagnosis
Able to provide consent in English

Exclusion Criteria:
Patients who are below 18 years
Patients who have a different type of diabetes either than type 2
Patients diagnosed with Type 2 diabetes more than 12 months
Newly diagnosed diabetes patients who have not attended diabetes self-management education
Diabetes & Hormones
I'm interested
Share via email

Concussion-Prognosis

Using micro-RNA in saliva coupled with survey data as a prognostic tool with the ability to guide clinical management of concussions

During their baseline visit participants will complete a saliva swab, surveys, balance test and brief neurocognitive test.Day 7, participants will complete a saliva swab and 2 surveys.Day 30, participants will complete a saliva swab and 4 surveys.The baseline visit is the only in-person visit, day 7 and day 30 are done remotely.All surveys are completed online and day 7 and day 30 saliva swabs are sent home with the participants and sent back in a prepaid mailer on day 30.

$40

Yes
 

Jayson Loeffert
Brennen Harding - at bharding@pennstatehealth.psu.edu or 717-531-5656
Family and Community Medicine (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT04582682
SITE00000820
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
13-18 years old
Diagnosis of concussion

Exclusion Criteria:
more than 48 hours after injury
Neurology, Sports Medicine
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Prospective Cohort Assessing Novel Biomarkers of Early Pregnancy

The purpose of this research is to take and store blood, urine samples from pregnant women diagnosed by a positive pregnancy test or by ultrasound imaging. The purpose of this study is to determine a better way to diagnose the location and/or viability (chance of survival) of a pregnancy, as compared to current clinical care. Many women are found to be pregnant by a hCG (human chorionic gonadotropin) test which detects a hormone that is indicative of pregnancy. However, in early pregnancy, it is often difficult to see the pregnancy by ultrasound, which is called a pregnancy of unknown location (PUL). In early pregnancy, doctors do many tests (including blood tests and ultrasounds) to try to determine how far along the pregnancy is, whether it is healthy, and most importantly whether the pregnancy is growing in the right place. The doctors running this research project are trying to see if there are substances (biomarkers) in the blood or urine of a pregnant woman that can tell whether the pregnancy is a normal, healthy pregnancy, an ectopic pregnancy, or if pregnancy is not viable (miscarriage). To do this, blood and/or urine samples are being collected from women who have a pregnancy of unknown location, an ectopic pregnancy, women who are having a miscarriage, and women with a healthy growing pregnancy. The study will then look at a pre- determined panel of biomarkers that have been shown to be elevated (higher) or decreased (lower) in different types of pregnancy to determine the effectiveness and accuracy of this test in earlier diagnosing the viability and location of early pregnancy.

There will be one visit at the visit participants will be consented and following consenting blood and urine will be collected.

$25.00

Yes
 

Sarah Horvath
OBGYN Research at OBGYNResearch@pennstatehealth.psu.edu or 717-531-0003, ext=320358
Obstetrics and Gynecology (HERSHEY)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00018551
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pregnancy diagnosed by a positive serum human chorionic gonadotropin (hCG) test
Live intrauterine pregnancy through 14 weeks, diagnosed by ultrasound demonstrating fetal heart motion
Diagnosed ectopic pregnancy
Pain or bleeding or at risk for ectopic pregnancy
Women seeking confimation of a pregnancy with a urine or serum pregnancy test (less than 14 weeks)

Exclusion Criteria:
Not a Penn State Health Patient
Pregnancy & Infertility, Women's Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

POSTA: Protocol for Oral Somatosensation and Texture Appreciation

The purpose of this study is to collect normative data related to orofacial (lip/tongue) somatosensation (touch sensation) in healthy adults across the adult lifespan. This data will be compared to a select clinical population, those with Parkinson's disease.

There will be one data collection session lasting approximately 90 minutes. Participants may be invited back for a second session approximately 4 weeks later to repeat the testing sessionDuring the sessions, participants will answer a series of questions about their eating and drinking preferences, they will be asked to provide a speech sample by repeating a series of syllables, words, and sentences, as well as providing a spontaneous speech sample.All participants will be asked to complete a series of sensory tests where small plastic objects are placed on their lip, tongue, and finger tip. Participants will be asked when they feel the pressure/texture and when they do not.

Yes
 

Nicole Etter
Nicole Etter - at oppal@psu.edu or 814-863-2021
Communication Sciences and Disorders (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00024173
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
English-speaking
Hearing and cognition within functional limits to complete speaking tasks
Clinical Group: Diagnosed with Parkinson's disease (PD)

Exclusion Criteria:
Have an injury to the lower face
have an active lesion to the lower face (ie cold sore, fever blister, etc)
have had a dental visit in the last month that involved general or local anesthesia to the oral region
exhibit symptoms of Tardive Dyskinesia secondary to anti-psychotic drug use
report current or recovering from a viral illness like Bell’s Palsy or Shingles
Food & Nutrition, Neurology
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Linking olfactory deficits to memory impairment and AD neurodegeneration

The purpose of this voluntary research study is to find out more about changes in the brain as we age. This study is trying to determine if magnetic resonance imaging (MRI), genetic variations, amyloid positron emissions tomography (PET), neuropsychological testing, and smell tests can be used to evaluate memory loss and cognitive impairment.

You will be asked to come to the research site once a year for 5 years.Annual (and semi-annual) procedures include completing smell tests, neuropsychological tests, magnetic resonance imaging (MRI). One-time procedures include provide blood sample, amyloid PET scan (if indicated), and optional lumbar puncture.

Up to $250 a year

Yes
 

Prasanna Karunanayaka
Rommy Elyan - at relyan@pennstatehealth.psu.edu
Radiology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00018557
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Individuals between ages 55-85

Exclusion Criteria:
Non-English speaking
Smell impairment
Women who are pregnant or breastfeeding
Currently smoke
Have claustrophobia
Neurology
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Mindfulness, Neuroscience and Daily Life Study

This study will examine whether a guided drawing activity helps to reduce anxiety in young adults. This will add to our understanding of how drawing can be used to manage anxiety symptoms and bolster emotion regulation. 

This study will require two in person lab visits that take approximately 2 hours each and separated by four weeks where participants will have their brain and heart rate activity monitored while completing mindfulness activities. After the first in person visit, participants will complete two 30 minute audio/questionnaire sessions a week for four weeks (8 total) before returning to the lab for the second visit where participants can expect to complete a similar experience as their first in person visit. Two weeks after the second in person lab visit, participants will complete a Qualtrics questionnaire that will take approximately 30 minutes to complete. Total overall participation of approximately 8 to 8 1/2 hours.

$175

Yes
 

Sarah Myruski
Margaret Penner - at mep5756@psu.edu
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT00000000
STUDY00025015
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults ages 18-25
Able to read, speak and write in English

Exclusion Criteria:
Those who are not yet 18 and 26 or over
Not able to read, speak and write in English
Neurology, Mental & Behavioral Health
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Accessibly of Conversational Agents with Deaf or Blind Users

Using small focus groups, this work aims to understand the experiences, challenges, perceptions, and opportunities for the use of conversational agents (e.g Amazon Alexa and Siri) for users with visual or hearing impairments, with the goal of developing more accessible and inclusive systems.

Yes
 

Johnna Blair
Johnna Blair - at jlb883@ist.psu.edu or 814-706-8412
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00010384
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Either, blind or visually impaired,
Or, hard of hearing or deaf using cochlear implant or other aided hearing device
Currently 18 years of age or older
English language speakers

Exclusion Criteria:
Minors, under the age of 18
Non-English language speakers
Language & Linguistics, Vision & Eyes
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

PSCI-22-042: M23-362 Epcoritamab monotherapy R/R DLBCL or Classic FL (Previously Grade 1-3a) outpatient

The purpose of this voluntary research study is to optimize the approach to safely administer a study drug called epcoritamab in the outpatient/non-hospital setting.

Complete interview, questionnaires, and subject diaryECGClinical laboratory testsBiopsy sample, archival or freshCT/PET-CT/MRITreatment of epcoritamab

Yes
 

Seema Naik
Laurie ONeal - at loneal1@pennstatehealth.psu.edu or 717-531-0003, ext=343429
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05451810
SITE00001234
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Subjects must voluntarily sign and date an informed consent,
Adult male or female, at least 18 years old
Diagnosis of R/R DLBCL or R/R FL grade 1, 2, or 3a, with documented CD20+ mature B-cell neoplasm according to WHO classification 2016 or WHO classification 2008 based on representative pathology report
Subject must have 1 or more measurable disease sites:  Fluorodeoxyglucose (FDG)-avid lymphomas:
Subject must have Eastern Cooperative Oncology Group (ECOG) performance status 0 – 2

Exclusion Criteria:
Central nervous system (CNS) involvement
inadequate organ functions
central nervous system involvement
history of primary mediastinal lymphoma.
history of severe allergic or anaphylactic reactions to anti-CD20 monoclonal antibody therapy.
Cancer
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Exploring the Immediate Psychosocial and Self-Management Support Needs of Individuals Newly Diagnosed with Type 2 Diabetes (T2D)

To find out the kind of support someone newly diagnosed with type 2 diabetes will need following diagnosis.

No
 

Michelle Boakye
Michelle Boakye - at mdb521@psu.edu or 814-699-1783
Nursing (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00017593
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
newly diagnosed with type 2 diabetes(past 12 months)
Age 20 years or older
agree to participate in online focus group

Exclusion Criteria:
old cases of type 2 diabetes
individuals below 20 years
diagnosed with other types of diabetes
Diabetes & Hormones
I'm interested
Share via email

Exploring International Students’ Development of English as a Lingua Franca Pragmatic Competence

This study explores how international students show and develop pragmatic strategies to effectively communicate with peers and colleagues from diverse language and cultural backgrounds at Penn State. Participants recruited from the StudyFinder are invited to complete an online survey, and will receive an Amazon gift card as a token of appreciation.

No
 

Shuyuan Liu
Shuyuan Liu - at szl290@psu.edu
Applied Linguistics (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00012216
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
International students enrolled at Penn State

Exclusion Criteria:
Is not an international students enrolled at Penn State
Education, Language & Linguistics
I'm interested
Share via email

Investigating the emotional and behavioral response in humans playing games against a humanoid robot

We would like to study the emotional and behavioral response of a human playing games against a robot. Games such as Connect Four and card games will be used.

Yes
 

Alan Wagner
Vidullan Surendran - at vus133@psu.edu
Aerospace Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00010076
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Over the age of 18
Physically and mentally able
Basic proficiency of english

Exclusion Criteria:
Under the age of 18
Unwilling to have video footage of the experiment taken
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Pennsylvania Adoptees Longitudinal Study (PALS)

This study will examine various factors within the home of children adopted from the child welfare system between the ages of 4 and 10 that may impact their development. The first visit will occur remotely via Penn State Health Microsoft Teams; the second visit is optional and will occur within 4 weeks of the first visit at the Transforming Lives of Children Center in Harrisburg, PA; and the third visit will occur one year after the first visit, when research staff will travel to participants' homes. This research will help understand the factors that impact the development of children adopted from the child welfare system and how we may better serve these children and their families.

The child and parent will be asked to complete interviews, questionnaires and various tasks. Parents may also be asked to complete questionnaires online.Participation will last for one year and include the following:-One visit occurring remotely via PSH Microsoft Teams-One visit at the Transforming the Lives of Children Center in Harrisburg, PA, four weeks after Zoom visit (optional)-Final visit at home will occur one year after the first Zoom visit

$225

Yes
 

Brian Allen
pals@pennstatehealth.psu.edu 717-531-0003, ext=321713
Pediatrics: Child Abuse (HERSHEY)
 

All
All
This study is also accepting healthy volunteers
STUDY00013344
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Child age between 4 and 10
Child legally adopted by the caregiver
The same caregiver will participate in each of the visits

Exclusion Criteria:
Child diagnosed with intellectual disability
A biological parent resides in the same home as the child
Children's Health, Mental & Behavioral Health
I'm interested
Share via email
Show 17 locations

Study Locations

Hide all locations
Location Contacts
Altoona, PA ,
Carlisle, PA ,
DuBois, PA ,
Erie, PA ,
Greater Philadelphia Area, PA ,
Greater Pittsburgh Area, PA ,
Harrisburg, PA ,
Hazleton, PA ,
Hershey, PA ,
Mont Alto, PA ,
Reading, PA ,
Schuylkill Haven, PA ,
Sharon, PA ,
State College, PA ,
Wilkes-Barre/Scranton Area, PA ,
Williamsport, PA ,
York, PA ,

Graduate Students’ Experience with Online Professional Profiles and Social Media

With the development of information and communication technologies, Social Network Sites and other online platforms can be great resources for career-related information and social networking. Despite the evidence of possible professional benefits, it remains unclear whether graduate students’ experiences with building online career profiles and social networking are positive. Therefore, this study aims to understand graduate students’ experience with professional practices on the Internet concerning their motivations, benefits, and risks.

No
 

Chuhao Wu
Chuhao Wu - at cjw6297@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00019028
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
An active graduate student at University Park campus

Exclusion Criteria:
NA
Education
I'm interested
Share via email

AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

This is a multicenter evaluation of seladelpar, administered as a once-daily oral capsule, in a placebo-controlled study in subjects with Primary Biliary Cholangitis (PBC). This study (156 weeks) will enroll approximately 192 subjects. The population to be studied is patients with PBC and compensated cirrhosis restricted to Child-Pugh (CP)-A or CP-B.Primary ObjectivesEfficacy: To evaluate the effect of seladelpar compared to placebo.Safety: To evaluate the safety of seladelpar over 156 weeks of treatment compared to placebo.Study visits: up to 18 in person visits. Blood samples will be collected at each visit for safety measures as well and questions about your health and medicines you might be taking.

There will be 18 in person visits. safety assessments will be conducted at each visit. Participants will be required to take study drug as directed.

$1350

Yes
 

Karen Krok
Laurie Peiffer - at lpeiffer@pennstatehealth.psu.edu or 717-531-5226
Medicine: Gastroenterology and Hepatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06051617
STUDY00022898
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
diagnosis of PBC
Elevated Alkaline Phosphatase (ALP)
documented cirrhosis

Exclusion Criteria:
history of liver transplant
decompensated cirrhosis
portal vein thrombosis
hospitalization for liver complication within 12 weeks
HIV
Digestive Systems & Liver Disease
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Modeling Transition Speeds in Elderly Human Walking

This study will involve elderly humans walking on a treadmill transitioning through prechosen speeds.

There will be one, two hour in person visit. Participants will change into specific lab provided clothing for study and reflective stickers will be placed on participants by the researcher. Participants will then get on the treadmill and will walk at prescribed constant speeds for about 5 minutes total. Then participants will perform 10 speed transition trials each of which lasts about 4 minutes.

$15

Yes
 

Ashley Zeman
Ashley Zeman - at apz5261@psu.edu or 724-759-1651
Division of Undergraduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00021984
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
65+ years old
Can continuously walk for up to 4 minutes
Be able to follow verbal instructions

Exclusion Criteria:
Active or existing neuromuscular, cardiovascular, vascular, or neurological pathologies, injuries, or illnesses affecting gait
High BMI (>30)
Neurology, Muscle & Bone
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)

This study is to determine the maximum tolerated dose (MTD) of MRTX849 using one or more dosing regimens. The regimens includ using MRTX849 or in combination with Afatinib, Cetuximab, or Pembrolizumab. The study will also look at how it can be tolerated MRTX849 when its taken with food.

If you take part in this research, your major responsibilities will include: •Keep your study appointments and complete all study assessments. If you cannot keep anappointment, please contact study personnel (your study doctor or study staff) as soon aspossible to schedule a new appointment.•Inform your study personnel about any symptoms, changes in medications, doctor's or nurse'sappointments, or hospital admissions that you may have had.•Agree to not participate in any other clinical research study•Inform study personnel if you believe you or your partner might be pregnant•Inform study personnel if you change your mind about participating in the study.•Inform your other doctors that you are taking part in this study.•Avoid grapefruit and grapefruit juice.•Avoid herbal medications and preparations including but not limited to St. John’s wort, Kava,turmeric/curcumin, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA),yohimbe (yohimbine), saw palmetto, and ginseng.•Avoid medications that are processed by liver enzymes, your doctor will counsel you on these.•Avoid medications known to have risk of changing the electrical activity in the heart, your doctorwill council you on these.•For your safety, you must tell the study doctor or nurse about all the prescription drugs, herbalproducts, over-the-counter drugs (OTC), vitamins and other supplements you are taking.Check with the study doctor before starting any new medicines (including prescription, OTCdrugs, vitamins and herbal supplements) or changing doses of medications that you arealready taking.

Yes
 

Patrick Ma
Irina Geier - at igeier@pennstatehealth.psu.edu or 717-531-8678
Molecular and Precision Medicine (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03785249
STUDY00014803
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation.
Unresectable or metastatic disease.
Presence of tumor lesions to be evaluated per RECIST 1.1:
Life expectancy of at least 3 months.
Eastern Cooperative Oncology Group (ECOG) performance status in 0 or 1.

Exclusion Criteria:
Active brain metastases.
Patients with carcinomatous meningitis
History of significant hemoptysis or hemorrhage within 4 weeks of the first dose date
Undergone major surgery within 4 weeks of first dose date
History of intestinal disease or major gastric surgery likely to alter absorption of study treatment or inability to swallow oral medications
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Campus Environments and Student Health

The purpose of this study is to learn about the relationship between the campus environment and students’ health. It involves a survey consisting questions about campus-related activities, COVID-19, physical activity and health, environmental perceptions, and demographic information.

There will be an online survey that will take about 20-30 minutes. No need to meet in-person.

No
 

Amaryllis Park
Amaryllis Park - at ahp5234@psu.edu or 281-628-6496
Landscape Architecture (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00022472
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Currently enrolled as a student (part-time or full-time)
At least 18 years old or older

Exclusion Criteria:
Younger than 18 years old
Mental & Behavioral Health
I'm interested
Share via email

Dysgeusia and Anosmia in Head and Neck Cancer Patients: Long Term Outcomes

The primary aim of this study is to understand taste changes after head and neck cancer treatment, especially long term taste disturbance, using various methods including online surveys, Teams interviews, at home taste and smell tests, and MRIs.

The purpose of this voluntary research study is to identify taste changes in patients treated for head and neck cancer. We are recruiting healthy participants over the age of 40 as well as head and neck cancer survivors who were treated 3 or more years ago. The overall study consists of multiple parts, which are explained along the way. You can choose to participate in this portion, which is an online survey, and nothing else, or all of the invited components. •The survey will take approximately 10 minutes of your time. •Completion of this survey is voluntary and you are not required to complete it if you do not wish to do so.•At the end of the survey you will be asked about your willingness to participate in other portions of this study. These include at-home taste and smell tests over Teams and a Teams interview about your taste and smell function. Participating in these tasks is optional and not required. If you complete the smell and taste tests at home you may be invited to have an MRI scan.

Max of $75: No compensation for the survey, $15 giftcard for 1-hour interview (optional), $15 giftcard for at-home taste/smell tests (optional), $50 giftcard for MRI at Hershey Med Center (optional).

No
 

Neerav Goyal
Hanel Eberly - at HNCtaste@pennstatehealth.psu.edu
Otolaryngology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00019457
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Able to give consent
Over the age of 40
English Speaking

Exclusion Criteria:
Under 40 years of age
have undergone a total glossectomy
currently have an upper respiratory infection, sinus infection, or ear infection
Cancer
I'm interested
Share via email

A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab.

Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype.

You will receive either study drug or placebo, undergo research-related tests and procedures, and questionnaires. You will need to visit the study center up to 18 times over a period of 15 months. You will have different tests and procedures throughout the study. The aim is to check on your health andsymptoms, check on your response to treatment and any side effects, and assess the study drug.This study will compare the study drug with either mepolizumab or benralizumab, known as the comparator medications. The effects of the drugs, both good and bad, will be compared. Study participants will be divided into 2 groups to receive:Study drug (once every 26 weeks) + placebo (once every 4 or 8 weeks) OR,Mepolizumab (once every 4 weeks) or benralizumab (once every 8 weeks) + placebo (once every 26 weeks).All participants will receive an active treatment. You will be assigned to receive either the study drug or comparator (mepolizumab or benralizumab) you were taking before the study. No participant previouslytaking mepolizumab will be assigned to benralizumab, and no participant previously taking benralizumab will be assigned to mepolizumab.

$183.00

Yes
 

Timothy Craig
Kristina Richwine - at krichwine@pennstatehealth.psu.edu or 717-531-4506
Medicine: Pulmonary, Allergy and Critical Care (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04718389
STUDY00017202
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults 18 years or older at the time of signing the informed consent.
Have a documented diagnosis of asthma for 2 or more years.
Receiving either mepolizumab or benralizumab for 12 or more months prior to screening.
A well-documented requirement for regular treatment with medium to high dose inhaled corticosteroid in the 12 months prior to Visit 1 with or without maintenance oral corticosteroid.
Current treatment with at least one additional controller medication, besides an inhaled corticosteroids.

Exclusion Criteria:
Concurrent respiratory disease
Eosinophilic diseases
Pregnancy
Current or former smokers with a smoking history of 10 or more years.
Active COVID-19 infection
Lung Disease & Asthma
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Foot mechanics during gait with load carriage and toe elevation

This experimental study will investigate foot joint function during walking and running and/or hopping and performing heel raises. Participants will walk and run and/or complete heel raises with mass added to their body and will walk and run and/or hop with a plastic wedge secured to the underside of their toes.

Participants will walk and run and/or complete heel raises with mass added to their body and will walk and run and/or hop with a plastic wedge secured to the underside of their toes.

Yes
 

Ben Perrin
Ben Perrin - at bkp5431@psu.edu or 919-389-9898
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00016164
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-35
Run > 10 kilometers/week for past 6 months
If participant does not fit running criteria: Lifted weights of at least one bodyweight using barbell >= 2x/week for past 6 months

Exclusion Criteria:
Have had previous lower limb surgery
Experienced pain with walking, running, or (if applicable) weightlifting in past 6 months
Have had plantar fasciitis
Have osteoarthritis in lower limb
Have had diabetes 1 or 2
Sports Medicine, Muscle & Bone
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Comparing Mechanisms of Pattern Learning

The purpose of the proposed plan of research is to investigate the types of patterns that human adults with or without a history of language/ learning difficulties tap into as they learn.

Our study involves an initial testing session lasting between 1-2 hours, followed by up to two additional sessions for eligible participants. As part of our study, you will take part in some speaking, listening, learning, and visual processing tasks.

up to $75

No
 

Roger Beaty
jzp6211@psu.edu
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00017229
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-28
Only speaks English fluently
Normal or corrected-to-normal vision/ hearing
Minimum of high school education
May have a history of language/ learning difficulties

Exclusion Criteria:
History of neurological injury or disease
Speaks more than one language
Under age 18
Over age 28
Does not have minimum of high school education
Language & Linguistics
Not applicable
I'm interested
Share via email

Emotion Regulation and Mother-Infant Synchrony

The aim of this study is to better understand emotion regulation in infants by measuring brain, behavior, and mother-infant relational mechanisms. We plan to collect simultaneous brain activation in mothers and infants while they engage in a face-to-face interaction. We will then test associations between individual brain activation, mother-infant brain synchrony, and infant emotion regulation behaviors.

Participants complete questionnaires online, then come in for 1 in-person visit. Mother and baby complete a play and a neutral task while fNIRS is collected from them simultaneously.

40

Yes
 

Berenice Anaya
Berenice Anaya - at bua25@psu.edu
Psychology (UNIVERSITY PARK)
 

All
All
This study is also accepting healthy volunteers
STUDY00018109
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Infants who are 4 months and their mother.
Infants born 3 weeks within their due date.
Infants of a birth weight > 2500 g.
Infants with NO serious medical complications.
English-speaking families.

Exclusion Criteria:
Infants who were < 2500 g at birth.
Infants who experienced any serious medical complications.
Infants who were born > 3 weeks before the indicated gestational period.
Families who do not understand and do not speak English
Children's Health, Neurology
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,